Evidence map›Paper›PMID 40938325›Full record

ArticleeLife2025

Spatial and longitudinal tracking of enhancer-AAV vectors that target transgene expression to injured mouse myocardium.

David W Wolfson, Joshua A Hull, Yongwu Li, Trevor J Gonzalez, Mourya D Jayaram, Garth W Devlin, Valentina Cigliola, Kelsey A Oonk, Alan Rosales, Nenad Bursac and 2 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

David W WolfsonDepartment of Cell Biology, Duke Regeneration Center, Duke University School of Medicine, Durham, United States.ORCID https://orcid.org/0000-0003-3850-3925
Joshua A HullDepartment of Surgery, Duke University School of Medicine, Durham, United States.
Yongwu LiDepartment of Biomedical Engineering, Duke University, Durham, United States.
Trevor J GonzalezDepartment of Surgery, Duke University School of Medicine, Durham, United States.
Mourya D JayaramDepartment of Surgery, Duke University School of Medicine, Durham, United States.
Garth W DevlinDepartment of Surgery, Duke University School of Medicine, Durham, United States.
Valentina CigliolaDepartment of Cell Biology, Duke Regeneration Center, Duke University School of Medicine, Durham, United States.
Kelsey A OonkDepartment of Cell Biology, Duke Regeneration Center, Duke University School of Medicine, Durham, United States.
Alan RosalesDepartment of Biomedical Engineering, Duke University, Durham, United States.
Nenad BursacDepartment of Biomedical Engineering, Duke University, Durham, United States.ORCID https://orcid.org/0000-0002-5688-6061
Aravind AsokanDepartment of Surgery, Duke University School of Medicine, Durham, United States.
Kenneth D PossDepartment of Cell Biology, Duke Regeneration Center, Duke University School of Medicine, Durham, United States.ORCID https://orcid.org/0000-0002-6743-5709

Funding

Project 3 - Role of Proline Metabolism in Regulation of Mammalian Cardiomyocyte ProliferationP01HL160476 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Hesham Sadek · 2022 to 2026
$13.1M
Determinants of AAV TropismR01HL089221 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Aravind Asokan · 2009 to 2026
$8.1M
Integrated Cellular and Tissue Engineering for Ischemic Heart DiseaseU01HL134764 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BURSAC, NENAD, KAMP, TIMOTHY J. · 2016 to 2022
$7.7M
Leveraging zebrafish models to dissect and enhance heart regenerationR35HL150713 · NHLBI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI KENNETH D POSS · 2020 to 2026
$6.9M
Dissecting AAV silencing in humanized miceR01DK134408 · NIDDK · DUKE UNIVERSITY · PI Aravind Asokan, Karl-Dimiter Bissig · 2023 to 2026
$2.4M
Engineering Human Heart Tissues with Polyploid CardiomyocytesR01HL164013 · NHLBI · DUKE UNIVERSITY · PI BURSAC, NENAD · 2022 to 2025
$2.2M
Engineered BacNav and BacCav for Improved Excitability and ContractionR01EB032726 · NIBIB · DUKE UNIVERSITY · PI BURSAC, NENAD · 2022 to 2025
$1.9M
NHLBI NIH HHS P01 HL160476NHLBI NIH HHS R01 HL089221NHLBI NIH HHS R01HL089221NHLBI NIH HHS R01 HL164013NHLBI NIH HHS R01HL164013NHLBI NIH HHS R35 HL150713NHLBI NIH HHS R35HL150713NHLBI NIH HHS U01 HL134764NHLBI NIH HHS U01HL134764NIBIB NIH HHS R01 EB032726NIBIB NIH HHS R01EB032726NIDDK NIH HHS R01 DK134408NIDDK NIH HHS R01DK134408
6 · The paper itself

Abstract

Tissue regeneration enhancer elements (TREEs) direct expression of target genes in injured and regenerating tissues. Additionally, TREEs of zebrafish origin were shown to direct expression of transgenes in border zone regions after cardiac injury when packaged into recombinant adeno-associated viral (AAV) vectors and introduced into mice. Future implementation of TREEs into AAV-based vectors as research tools and potential gene therapy modalities requires a deeper understanding of expression dynamics and potential off-target effects. Here, we applied in vivo bioluminescent imaging to mice systemically injected with AAV vectors containing different combinations of capsids, enhancers, and timing of delivery. Longitudinal tracking of expression directed by different TREEs revealed distinct amplitudes and durations of reporter gene expression in the injured heart. The liver-de-targeted AAV capsid, AAV.cc84, could deliver TREEs either pre- or post-cardiac injury to negate off-target expression in the liver while maintaining transduction in the heart. By screening AAV9-based capsid libraries dosed systemically in mice post-cardiac injury, we discovered a new capsid variant, AAV.IR41, with enhanced transduction in cardiac injuries and with elevated transduction of TREE-driven transgenes versus conventional AAV9 vectors. In vivo bioluminescence imaging offers insights into how enhancers and engineered capsids can be implemented to modulate spatiotemporal transgene expression for targeted therapies.

Indexed as

DependovirusEnhancer Elements, GeneticGene ExpressionGenetic VectorsHeart InjuriesMyocardiumTransgenesAnimalsGenetic TherapyMiceMice, Inbred C57BLAAV capsidsdevelopmental biologyenhancergene expressionheartheart regenerationmouseregenerationregenerative medicinestem cells

Identifiers

PMID40938325
PMCPMC12431772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.